Regenxbio Target of Unusually Large Options Trading (RGNX)

Regenxbio Inc (NASDAQ:RGNX) was the target of some unusual options trading activity on Monday. Stock traders acquired 2,330 call options on the company. This represents an increase of 3,182% compared to the average volume of 71 call options.

RGNX has been the subject of several research analyst reports. Bank of America lowered shares of Regenxbio from a “buy” rating to a “neutral” rating and increased their price objective for the company from $64.00 to $80.00 in a research report on Monday, July 23rd. BidaskClub lowered shares of Regenxbio from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 25th. Chardan Capital decreased their price objective on shares of Regenxbio from $130.00 to $127.50 and set a “buy” rating for the company in a research report on Wednesday, August 8th. ValuEngine raised shares of Regenxbio from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 10th. Finally, Barclays increased their price objective on shares of Regenxbio from $48.00 to $83.00 and gave the company an “overweight” rating in a research report on Monday, August 13th. Four equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $82.93.

Shares of Regenxbio stock opened at $59.92 on Tuesday. The company has a market capitalization of $2.32 billion, a P/E ratio of -24.46, a P/E/G ratio of 9.85 and a beta of -0.49. Regenxbio has a 52 week low of $23.25 and a 52 week high of $85.10.

Regenxbio (NASDAQ:RGNX) last posted its quarterly earnings results on Wednesday, November 7th. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.30. Regenxbio had a net margin of 44.30% and a return on equity of 22.52%. The company had revenue of $5.31 million during the quarter. As a group, research analysts anticipate that Regenxbio will post 2.16 earnings per share for the current fiscal year.

In related news, CFO Vittal Vasista sold 7,500 shares of the stock in a transaction that occurred on Monday, September 17th. The shares were sold at an average price of $74.86, for a total value of $561,450.00. Following the completion of the transaction, the chief financial officer now directly owns 120,722 shares of the company’s stock, valued at approximately $9,037,248.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Curran Simpson sold 62,309 shares of the stock in a transaction that occurred on Tuesday, October 16th. The shares were sold at an average price of $60.85, for a total transaction of $3,791,502.65. Following the completion of the transaction, the senior vice president now directly owns 86,017 shares of the company’s stock, valued at $5,234,134.45. The disclosure for this sale can be found here. Insiders sold a total of 301,585 shares of company stock worth $19,708,531 over the last 90 days. Company insiders own 16.90% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Teachers Advisors LLC raised its position in Regenxbio by 6.5% during the 3rd quarter. Teachers Advisors LLC now owns 221,979 shares of the biotechnology company’s stock worth $16,759,000 after buying an additional 13,537 shares during the last quarter. AQR Capital Management LLC raised its position in Regenxbio by 20.4% during the 3rd quarter. AQR Capital Management LLC now owns 211,830 shares of the biotechnology company’s stock worth $15,993,000 after buying an additional 35,915 shares during the last quarter. Thrivent Financial for Lutherans raised its position in Regenxbio by 11.1% during the 3rd quarter. Thrivent Financial for Lutherans now owns 20,438 shares of the biotechnology company’s stock worth $1,543,000 after buying an additional 2,035 shares during the last quarter. MetLife Investment Advisors LLC raised its position in Regenxbio by 66.9% during the 3rd quarter. MetLife Investment Advisors LLC now owns 22,065 shares of the biotechnology company’s stock worth $1,666,000 after buying an additional 8,848 shares during the last quarter. Finally, Redmile Group LLC raised its position in Regenxbio by 6.1% during the 3rd quarter. Redmile Group LLC now owns 1,656,065 shares of the biotechnology company’s stock worth $125,033,000 after buying an additional 94,890 shares during the last quarter. 75.92% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Regenxbio Target of Unusually Large Options Trading (RGNX)” was reported by WKRB News and is the sole property of of WKRB News. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of US & international copyright law. The correct version of this piece of content can be viewed at https://www.wkrb13.com/2018/11/20/regenxbio-target-of-unusually-large-options-trading-rgnx.html.

Regenxbio Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.

Read More: Moving Average (MA)

Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply